Migraine and Triptans

Deep Dive

From a Western clinical perspective, migraine is a neurovascular disorder characterized by cortical hyperexcitability and activation of the trig... From a Western clinical perspective, migraine is a neurovascular disorder characterized by cortical hyperexcitability and activation of the trigeminovascular system. This activation releases vasoactive neuropeptides—particularly CGRP—leading to sterile neurogenic inflammation and sensitization of pain pathways. Triptans directly target this cascade as selective agonists at serotonin 5‑HT1B/1D (and variably 1F) receptors on trigeminal terminals and cranial vessels. By curbing CGRP release, inhibiting nociceptive transmission in the trigeminal nucleus caudalis, and reversing pathologic cranial vasodilation, they shorten attacks and alleviate photophobia, phonophobia, and nausea. Robust randomized trials and meta‑analyses show that all marketed triptans outperform placebo for short‑term relief; however, their profiles differ. Subcutaneous sumatriptan delivers the fastest onset and highest early response, making it well‑suited to explosive attacks or those with vomiting. Oral rizatriptan and eletriptan often rank highly for two‑hour pain freedom, while longer‑acting naratriptan and frovatriptan may reduce recurrence at the cost of slower onset. Non‑oral nasal sprays and powders help when gastric stasis impairs absorption. Clinical strategy prioritizes treating early, matching formulation to the attack, and considering combination therapy. Co‑administration with naproxen enhances efficacy and durability, and antiemetics improve both symptoms and pharmacokinetics. Safety remains paramount. Because 5‑HT1B activation can constrict coronary and other arteries, triptans are contraindicated in ischemic heart disease, cerebrovascular disease, peripheral vascular disease, and uncontrolled hypertension, and are not labeled for hemiplegic or migraine with brainstem aura. They should not be combined within 24 hours with ergot derivatives or another triptan. Interactions include increased rizatriptan exposure with propranolol, CYP3A4 inhibition concerns for eletriptan, and MAO‑A interactions for several triptans. Although warnings about serotonin syndrome with SSRIs/SNRIs persist, large observational data suggest very low absolute risk; counseling and monitoring are appropriate. In pregnancy and lactation, sumatriptan holds the most reassuring (though not definitive) data; shared decision‑making is standard. When triptans are ineffective, poorly tolerated, overused, or contraindicated, alternatives include ditans (lasmiditan) and gepants (ubrogepant, rimegepant, zavegepant) that act without vasoconstriction. Preventive therapies—CGRP monoclonal antibodies, topiramate, beta‑blockers, onabotulinumtoxinA—reduce attack frequency and limit medication‑overuse headache, a recognized risk when triptans are used on ≥10 days per month for several months.